戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 signaling in response to the bacterial motif muramyl dipeptide.
2 B patients show an increased response to the muramyl dipeptide.
3 e recognition of bacterial cell wall-derived muramyl dipeptide.
4 n of the IL-1 receptor plus the co-stimulant muramyl dipeptide.
5 pon treatment of cells with the NOD2 ligand, muramyl dipeptide.
6 fibroblasts show an increased sensitivity to muramyl dipeptide.
7 owing NOD2-mediated recognition of bacterial muramyl dipeptide.
8 sease were deficient in their recognition of muramyl dipeptide.
9 d to lipopolysaccharide but not to synthetic muramyl dipeptide.
10                        NOD2 is able to sense muramyl dipeptide, a specific bacterial cell wall compon
11 tive bacterial cell wall, while NOD2 detects muramyl dipeptide, a ubiquitous cell wall peptidoglycan
12 step mechanism, requiring microbial product, muramyl-dipeptide, a component of peptidoglycan, followe
13 gh its WD-40 domain, binds to NOD2 following muramyl dipeptide activation.
14 ecular mechanisms that underlie detection of muramyl dipeptide and assembly of NOD2-containing signal
15 ombinant protein is able to bind directly to muramyl dipeptide and can associate with known NOD2-inte
16 39iCstop) are impaired in the recognition of muramyl dipeptide and Enterococcus faecalis, a commensal
17                           Binding of NOD2 to muramyl dipeptide and homo-oligomerization of NOD2 are e
18           However, agonists of NOD2, such as muramyl dipeptide and lysine-containing muramyl tripepti
19 , no significant binding was evident between muramyl dipeptide and NOD1.
20 binding of nucleotide followed by binding of muramyl dipeptide and oligomerization of NOD2 into a sig
21  polymeric form rather than monomers such as muramyl dipeptide and require PGN lysosomal hydrolysis t
22 onstrate that peptidoglycan monomers such as muramyl dipeptide and soluble peptidoglycan fail to indu
23 of a specific bacterial cell wall component, muramyl dipeptide, and activation of Nod2 stimulates an
24 uding lipopolysaccharide, lipoteichoic acid, muramyl dipeptide, and heat shock proteins.
25 s anthracis lethal toxin, Toxoplasma gondii, muramyl dipeptide, and host intracellular ATP depletion.
26 hypophagic agents, lipopolysaccharide (LPS), muramyl dipeptide, and interleukin-1, when challenged on
27 nges induced by the specific Nod2 activator, muramyl dipeptide, and that the role of NIK occurs in se
28                                              Muramyl dipeptides as well as the major muramyl tetrapep
29 promiscuous T-cell epitope (ie, MVF) and nor-muramyl-dipeptide as adjuvant emulsified in SEPPIC ISA 7
30 in-containing protein 2 (NOD2) by its ligand muramyl dipeptide, as compared to activation via heterod
31 TZ-injected WT mice received the NOD2 ligand muramyl dipeptide, both hyperglycemia and the proinflamm
32 rose-immobilized muramyl dipeptide or GlcNAc-muramyl dipeptide but not to PGN pentapeptide.
33 idoglycan (PGN), a TLR2 ligand that contains muramyl dipeptide, but not other TLR ligands; in contras
34 ptidoglycan are mediated by detection of its muramyl dipeptide component in the cytosol by NOD2, we r
35 lthough Zn(2+) is required for hydrolysis of muramyl dipeptide, disulfide oxidation is not required f
36 lysaccharide, lipoteichoic acid, lipid A and muramyl dipeptide elicit cryptdin secretion.
37 caspase recruitment domain (CARD) 15 detects muramyl dipeptide from bacterial peptidoglycans and medi
38 ignal transduction properties in response to muramyl dipeptide in cellular assays.
39 ctivation after the recognition of bacterial muramyl dipeptide in intestinal epithelial cells.
40      Costimulation of monocytes with LPS and muramyl dipeptide induced an enhanced IL-6 response that
41  both RIP2 tyrosine phosphorylation and MDP (muramyl dipeptide)-induced cytokine release in a variety
42 The dominant negative form of TAK1 abolished muramyl dipeptide-induced NF-kappaB activation in Nod2-e
43 s attenuates heightened ITCH(-/-) macrophage muramyl dipeptide-induced responses.
44                  Its activation by bacterial muramyl dipeptide induces expression of proinflammatory
45 ty mediated by Nod2 recognition of bacterial muramyl dipeptide is abolished in Nod2-deficient mice.
46  NOD2-dependent recognition of S. aureus and muramyl dipeptide is facilitated by alpha-toxin (alpha-h
47                                      Because muramyl dipeptide is the essential structure of peptidog
48               Bacterial proteoglycan-derived muramyl dipeptide (MDP) activates the intracellular NOD2
49 ty is based on previous studies showing that muramyl dipeptide (MDP) activation of NOD2 negatively re
50 production by human monocytes activated with muramyl dipeptide (MDP) adjuvant, which activates cytoso
51 ffectiveness of lipopolysaccharide (LPS) and muramyl dipeptide (MDP) administered into the brain to i
52 n-2 (NOD2) receptor detects bacteria-derived muramyl dipeptide (MDP) and activates the transcription
53 transports small bacterial peptides, such as muramyl dipeptide (MDP) and l-Ala-gamma-D-Glu-meso-diami
54 nts of bacterial peptidoglycan (PGN), namely muramyl dipeptide (MDP) and muramyl tripeptide (MTP).
55 ogenic bacterial cell wall (BCW) components, muramyl dipeptide (MDP) and peptidoglycan (PG).
56 orphisms may affect sensing of the bacterial muramyl dipeptide (MDP) and trigger perturbed inflammato
57 ands similar to the minimal synthetic ligand muramyl dipeptide (MDP) are generated by internalization
58 ling and autophagy activation in response to muramyl dipeptide (MDP) by immunoblot, confocal microsco
59                              NOD2 recognizes muramyl dipeptide (MDP) derived from bacterial peptidogl
60 R4 and Nod2 signaling by exposure to LPS and muramyl dipeptide (MDP) exhibit impaired TNF-alpha and I
61  (P.g.)-induced TNF-alpha can be affected by muramyl dipeptide (MDP) in a biphasic concentration-depe
62  show that activation of Nod2 by its ligand, muramyl dipeptide (MDP) in the bacterial cell wall, indu
63 ase in response to the presence of bacterial muramyl dipeptide (MDP) in the host cell cytoplasm, ther
64                                              Muramyl dipeptide (MDP) is a peptidoglycan moiety derive
65 he synergistic effect of IL-32 and synthetic muramyl dipeptide (MDP) on cytokine production was absen
66 ria produce an unusual, glycolylated form of muramyl dipeptide (MDP) that is more potent and efficaci
67 LR), is an intracellular sensor of bacterial muramyl dipeptide (MDP) that was suggested to promote se
68  contrast, ApoE(-/-) mice injected i.p. with Muramyl DiPeptide (MDP) to stimulate NOD2 and given an o
69          Here we investigated the effects of muramyl dipeptide (MDP), a bacterial cell wall component
70 n important role in innate immunity to sense muramyl dipeptide (MDP), a component of bacterial cell w
71 n of primary monocyte-derived macrophages by muramyl dipeptide (MDP), a component of bacterial peptid
72  receptor, induces autophagy on detection of muramyl dipeptide (MDP), a component of microbial cell w
73              We found that pretreatment with muramyl dipeptide (MDP), a ligand for Nod2, significantl
74 orm of mycobacterial cell wall component and muramyl dipeptide (MDP), a peptidoglycan derivative resp
75 n domain-containing protein 2 (NOD2) agonist muramyl dipeptide (MDP), a peptidoglycan motif common to
76     Four decades ago, it was identified that muramyl dipeptide (MDP), a peptidoglycan-derived bacteri
77                                              Muramyl dipeptide (MDP), a product of bacterial cell-wal
78 quently, we determined that the NOD2 ligand, muramyl dipeptide (MDP), activates NF-kappaB in primary
79   Nod2 is required for an immune response to muramyl dipeptide (MDP), an immunostimulatory fragment o
80  components, such as the NOD2 cognate ligand muramyl dipeptide (MDP), and are selectively required fo
81  we focus on the minimal bioactive PGN motif muramyl dipeptide (MDP), found in both Gram-positive and
82  an intracellular sensor of bacteria-derived muramyl dipeptide (MDP), increase susceptibility to Croh
83 ost recognition of its peptidoglycan-derived muramyl dipeptide (MDP), it masks the endogenous NOD-1 l
84 ciated molecular patterns (PAMPs), including muramyl dipeptide (MDP), LPS, and a B-class CpG oligonuc
85 ls were given an intraarticular injection of muramyl dipeptide (MDP), peptidoglycan (PG; a metabolite
86 nse of peripheral blood mononuclear cells to muramyl dipeptide (MDP), the ligand for NOD2.
87                                              Muramyl dipeptide (MDP), the microbial activator of nucl
88 ion in primary human mononuclear cells, with muramyl dipeptide (MDP), the minimal NOD2/CARD15 activat
89                                              Muramyl dipeptide (MDP), the NOD2 agonist, induces NF-ka
90  One such receptor, NOD2, via recognition of muramyl dipeptide (MDP), triggers a distinct network of
91 whole-genome level by microarray analysis of muramyl dipeptide (MDP)-treated Itch(-/-) primary macrop
92 innate immune activation by GMTriP-K but not muramyl dipeptide (MDP).
93 duction in response to i.p. and intravitreal muramyl dipeptide (MDP).
94 r of a component of the bacterial cell wall, muramyl dipeptide (MDP).
95 r 2, which recognizes the bacterial derivate muramyl dipeptide (MDP).
96 aspase-1, which responds to bacterial ligand muramyl-dipeptide (MDP).
97 for the phosphorylation of IRF5 by microbial muramyl-dipeptides (MDP), the minimal structural motif o
98 e NOD1 ligand MurNAcTri(DAP) and NOD2 ligand muramyl dipeptide [MDP]) but not bacterial Toll-like rec
99                                 In contrast, muramyl dipeptide-mediated inflammasome formation is not
100 ochemical and functional analyses identified muramyl dipeptide (MurNAc-L-Ala-D-isoGln) derived from p
101 is and tissue damage, whereas treatment with muramyl dipeptide (NOD2 ligand), which increases PMo mas
102 so specifically bound to agarose-immobilized muramyl dipeptide or GlcNAc-muramyl dipeptide but not to
103 eveloped tolerance to repeated injections of muramyl dipeptide or LPS and were cross-tolerant to S-O-
104  (a metabolite of which is the NOD2 agonist, muramyl dipeptide), or synthetic TLR2/1 and TLR2/6 agoni
105 hole-blood stimulation with the NOD2 ligand, muramyl dipeptide, or B. pseudomallei.
106 amma-d-glutamyl-meso-diaminopimelic acid and muramyl dipeptide, respectively).
107  of the peptidoglycan fragments meso-DAP and muramyl dipeptide, respectively, and drive the activatio
108 amma-d-glutamyl-meso-diaminopimelic acid and muramyl dipeptide, respectively.
109  with ZNRF4 under either 55 unstimulated and muramyl dipeptide-stimulated conditions.
110 and Nod2(-/-) macrophages were refractory to muramyl dipeptide stimulation.
111              Stimulation of macrophages with muramyl dipeptide, the Nod2 activator, enhanced immune r
112      In mice, SLIT2 attenuates the uptake of muramyl dipeptide, thereby preventing NOD2-dependent act
113 soGln for L-isoGln eliminated the ability of muramyl dipeptide to stimulate NOD2, indicating stereose
114 hogen-free facility, were given antibiotics, muramyl dipeptide (to stimulate NOD2), or dextran sodium
115                                              Muramyl dipeptide was recognized by NOD2 but not by TLR2
116 )CSK(4), a TLR2 ligand that does not contain muramyl dipeptide, were normal.
117 djuvant activity in mice, surpassing that of muramyl dipeptide, while achieving a more balanced Th1/T

 
Page Top